Contents

  1. Executive summary for the Pharmaceutical Needs Assessment (PNA) 2025
  2. Section 1: Introduction
  3. Section 2: Context for the PNA
  4. Section 3: NHS pharmaceutical services provision, currently commissioned
  5. Section 4: Other services that may impact on pharmaceutical services provision
  6. Section 5: Findings from the public questionnaire
  7. Section 6: Analysis of health needs and pharmaceutical service provision
  8. Section 7: Conclusions
  9. Appendix A: List of pharmaceutical service providers in Bexley by locality
  10. Appendix B: PNA project plan
  11. Appendix C: PNA Steering Group terms of reference
  12. Appendix D: Public questionnaire
  13. Appendix E: Consultation stakeholders
  14. Appendix F: Summary of consultation responses
  15. Appendix G: Consultation comments
  16. Appendix H: List of Abbreviations

11. Appendix C: PNA Steering Group terms of reference

Objective/Purpose

To support the production of the Pharmaceutical Needs Assessment (PNA) on behalf of the Bexley Health and Wellbeing Board (HWB), to ensure that it satisfies the relevant regulations including consultation requirements.

Delegated responsibility

The Director of Public Health confirmed they have received delegated authority for the PNA from the Health and Wellbeing Board.

Accountability

The Steering Group is to report to the Consultant in Public Health.

Responsibilities

  • provide a clear and concise PNA process
  • review and validate information and data on population, demographics, pharmaceutical provision, and health needs
  • to consult with the bodies stated in Regulation 8 of The NHS Regulations 2013:
    • any Local Pharmaceutical Committee (LPC) for its area
    • any Local Medical Committee for its area
    • any LPS Chemist in its area
    • any Local Healthwatch organisation for its area
    • any NHS Trust or NHS Foundation Trust in its area
    • integrated Care Boards
    • any neighbouring HWB
  • ensure that due process is followed
  • report to Health and Wellbeing Board on both the draft and final PNA
  • publish the final PNA by 1 October 2025

Membership

Core members:

  • Consultant in Public Health/Nominated Public Health Lead
  • NHSE Representative
  • Local Pharmaceutical Committee representative
  • Integrated Care Board Pharmacy and Medicines Optimisation representative
  • Healthwatch representative (lay member) 

Soar Beyond are not to be a core member however will chair the meetings. Each core member has one vote. The Public Health representative will have the casting vote, if required. Core members may provide a deputy to meetings in their absence. The Steering Group shall be quorate with three core members in attendance, one of which must be an LPC representative. Non-attending members are unable to cast a vote – that vote may otherwise sway the casting decision.

Additional members (if required):

  • Integrated Care Board Commissioning Managers
  • NHS Trust Chief Pharmacists

In attendance at meetings will be representatives of Soar Beyond Ltd who have been commissioned by LBB to support the development of the PNA. Other additional members may be co-opted if required.

Frequency of meetings

Meetings will be arranged at key stages of the project plan. The Steering Group will meet in summer 2025 to sign off the PNA for submission to the Health and Wellbeing Board.